Post-Finasteride Syndrome: Symptoms, Mechanisms and What UK Men Should Know

Post-finasteride syndrome (PFS) describes a cluster of symptoms that some men report continuing after they stop taking finasteride. The defining feature is that the symptoms persist, or sometimes begin, after the drug has been discontinued. It is not the same as side effects that resolve while still on the medicine. PFS is not currently recognised as a coded diagnosis by the NHS, but that does not mean the experiences of men who report it should be dismissed.

What symptoms are reported#

The most consistent finding across case series and patient reports is persistent sexual dysfunction. This typically includes reduced libido, erectile problems, or loss of spontaneous erections.

Other symptoms that have been described include:

• Depression, anxiety, and emotional blunting
• Cognitive difficulties, sometimes called brain fog
• Fatigue and muscle weakness
• Sleep disturbances
• Breast tenderness or mild enlargement

Diagnostic criteria proposed by Healy et al. in 2022 require sexual dysfunction to last at least three months after stopping finasteride. These criteria are not NHS policy, but they give researchers a working framework.

Symptoms vary considerably between individuals. They can also overlap with anxiety, low testosterone, depression, or other conditions unrelated to finasteride, which makes PFS difficult to diagnose with confidence.

The biological mechanisms proposed#

Finasteride blocks an enzyme called 5-alpha reductase. This enzyme converts testosterone into dihydrotestosterone (DHT), which drives hair follicle miniaturisation in male pattern baldness.

But 5-alpha reductase does more than produce DHT. It also plays a role in synthesising neurosteroids: brain-active compounds that regulate mood and cognition. One key neurosteroid affected is allopregnanolone, which is derived from progesterone via this same enzyme pathway. Reduced allopregnanolone activity has been linked to depression and anxiety in separate research.

Some researchers propose that finasteride use may cause lasting changes to androgen receptor sensitivity or gene expression, even after DHT levels return to normal. A 2022 case series in Translational Andrology and Urology identified genetic variants affecting androgen signalling in a small group of PFS patients, though sample sizes were too small to draw firm conclusions.

None of these mechanisms have been confirmed as the definitive cause of PFS. They are working hypotheses, not established facts.

How common is PFS and how long does it last#

Persistent side effects appear to be uncommon. In the large randomised controlled trials used to license finasteride, sexual side effects occurred in roughly 3.8% of men taking 1mg and resolved in most cases after stopping.

Irwig and Kolukula (2011, Journal of Sexual Medicine) reported persistent sexual side effects in a self-selected group of men who had stopped finasteride. Kiguradze et al. (2017, PeerJ) found persistent erectile dysfunction in a subset of men who had taken either finasteride or dutasteride, though the study relied on healthcare records rather than prospective follow-up.

PFS case numbers cited in media or advocacy sources tend to rely on self-report registries rather than population data, so any specific worldwide figure should be treated cautiously. The true prevalence is not known.

As for duration, documented cases range from months to years. Some men report gradual improvement; others describe symptoms that remain stable for extended periods. There is no reliable data on what proportion fully recover.

Does 1mg differ from 5mg in terms of risk#

The hair loss dose is 1mg daily. The dose used for enlarged prostate (benign prostatic hyperplasia) is 5mg daily. Both doses reduce DHT significantly, but the higher dose produces a greater reduction in circulating DHT.

The large licensed trial data (including the Prostate Long-term Efficacy and Safety Study, or PLESS) was conducted at 5mg. PFS reports exist at both doses. There is no clinical evidence clearly showing that 1mg carries a lower risk of PFS than 5mg. The difference in DHT suppression is real, but whether that translates to a meaningful difference in persistent side effect risk is not established.

The nocebo effect: a genuine and separate consideration#

A nocebo effect occurs when negative expectations cause a person to experience harm they might not otherwise have noticed. Mondaini et al. (2007) conducted a prospective study in which men told they might experience sexual side effects reported them at significantly higher rates than men who were not given that information. This was not a randomised design, but it raised an important point about expectation and symptom reporting.

Online forums devoted to PFS can create a concentrated, distressing picture that is not representative of most men's experience. That is not to dismiss the men in those communities. Their symptoms are real to them, and some likely do represent genuine pharmacological effects. But it is worth knowing that reading about a side effect can sometimes increase the chance of noticing and reporting it.

What the MHRA and UK prescribing information say#

The current UK prescribing information for finasteride 1mg includes warnings about persistent sexual side effects, including cases reported after stopping the medicine. UK patients can report any suspected adverse drug reaction directly to the MHRA through the Yellow Card scheme at yellowcard.mhra.gov.uk. This is free, takes around ten minutes, and is open to patients as well as healthcare professionals. Reports contribute to ongoing pharmacovigilance and help regulators identify patterns that trials may miss.

If you think you have PFS: the practical NHS pathway#

PFS does not currently have a specific NHS diagnostic code or funded treatment pathway. If you present to your GP with persistent symptoms after stopping finasteride, they are likely to investigate other causes first: testosterone levels, thyroid function, depression, and sleep disorders. That is appropriate clinical practice, not dismissal.

Your GP can refer you to a urologist, endocrinologist, or sexual health clinic depending on your main symptoms. Under the GMC's duty of candour, your doctor has a professional obligation to discuss known risks with you and to take your concerns seriously.

If depression or cognitive symptoms are prominent, NHS Talking Therapies (previously called IAPT) can be accessed via GP referral or self-referral in many areas.

Weighing up the decision#

For most men, finasteride is effective and well tolerated. Clinical trial data consistently show it slows or stops hair loss in a substantial majority of men who use it, and most side effects that do occur resolve after stopping.

For a small number, symptoms persist. The mechanism is not fully understood, and there is no reliable way to predict in advance who might be affected.

If you are considering finasteride and want to discuss your individual risk, Totiva's hair loss service is run by GPhC-registered UK clinicians who can talk through the evidence and help you decide whether treatment is appropriate. The service is available to men aged 18 and over. You can also read more about the broader side effect profile in the Totiva guide on finasteride side effects before making a decision.